This stock rockets 260% after $900 million mega crypto deal

Core Viewpoint - Sonnet BioTherapeutics is pivoting into the cryptocurrency sector through a significant business combination valued at $888 million, leading to a substantial increase in its stock price [1][2]. Group 1: Business Combination Details - Sonnet has entered into an agreement with Rorschach I LLC to form Hyperliquid Strategies Inc. (HSI), which will focus on cryptocurrency treasury operations [2]. - The transaction includes HSI holding approximately 12.6 million HYPE tokens valued at around $583 million and at least $305 million in cash at closing [3]. - The total valuation of the transaction is $888 million [3]. Group 2: Market Reaction - Following the announcement, Sonnet's stock price surged by 265%, reaching a pre-market high of $18.68, up from a closing price of $5.17 [1]. - Year-to-date, SONN shares have gained over 220% [1]. Group 3: Investor Participation - The transaction has attracted notable participation from prominent crypto investors, including Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital [4]. Group 4: Leadership Structure - HSI's leadership will include Bob Diamond as Chairman of the Board and David Schamis as CEO, with additional board members including Eric Rosengren, former President of the Boston Federal Reserve [5]. Group 5: Future Plans - HSI plans to utilize its capital to acquire more HYPE tokens, aiming to become one of the largest strategic holders of the asset [6]. - The transaction is expected to close in the coming months, pending regulatory and shareholder approvals [6].